Latest European Market Entry News

Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

AML3D Limited has reported a strong December quarter marked by significant defense contract completions, a $30 million capital raise, and strategic expansion into the US and European markets. The company is poised for accelerated growth, underpinned by a major US Navy funding boost and new sector entries.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Vection Technologies has secured a key distribution agreement to enter the Bulgarian market and partnered with DigiLens to integrate XR apps into advanced smart glasses, signaling a strategic push into Europe and global industrial sectors.